छोड़कर सामग्री पर जाएँ

Riding on Novo Nordisk’s semaglutide, India’s weight-loss market triples in size in 2 years

Semgalutide has almost 66 percent of the market share in the anti-obesity segment.

Read More

​ Semgalutide has almost 66 percent of the market share in the anti-obesity segment. Semgalutide has almost 66 percent of the market share in the anti-obesity segment.  Moneycontrol Latest News Read More  

Top 100 Best Sellers

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी
en_USEnglish hi_INहिन्दी